Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded at HC Wainwright

Key Points

• HC Wainwright has reiterated a "Buy" rating for Ultragenyx Pharmaceutical with a price target of $80.00, indicating an upside potential of 192.61% from its recent closing price.
• Several analysts have issued differing price targets and ratings, with an average company rating of "Moderate Buy" and an average price target of $82.57.
• Ultragenyx's most recent quarterly earnings report showed a loss of ($1.57) EPS, which missed analysts' expectations, despite a 28.0% year-over-year revenue increase to $139.29 million.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) was upgraded by equities researchers at HC Wainwright to a "buy" rating in a research note issued on Monday, Marketbeat.com reports. The firm currently has a $80.00 price target on the biopharmaceutical company's stock. HC Wainwright's price target would suggest a potential upside of 192.73% from the stock's previous close. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical's Q2 2025 earnings at ($1.27) EPS, Q3 2025 earnings at ($1.25) EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($5.14) EPS, Q1 2026 earnings at ($1.83) EPS, Q2 2026 earnings at ($1.59) EPS, Q3 2026 earnings at ($1.41) EPS, Q4 2026 earnings at ($1.05) EPS and FY2026 earnings at ($5.88) EPS.

Several other brokerages have also issued reports on RARE. Wedbush decreased their target price on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research report on Monday, July 14th. Morgan Stanley decreased their target price on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. William Blair began coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 price objective for the company. Wells Fargo & Company decreased their price objective on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a report on Thursday, July 10th. Finally, Guggenheim reissued a "buy" rating and issued a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $82.57.

Ultragenyx Pharmaceutical Stock Performance

Shares of Ultragenyx Pharmaceutical stock traded up $0.19 on Monday, hitting $27.33. The stock had a trading volume of 900,442 shares, compared to its average volume of 1,255,590. The firm has a market capitalization of $2.58 billion, a P/E ratio of -4.66 and a beta of 0.26. The stock has a 50 day moving average of $34.29 and a 200 day moving average of $37.40. Ultragenyx Pharmaceutical has a twelve month low of $25.81 and a twelve month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). The business had revenue of $139.29 million for the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. Ultragenyx Pharmaceutical's quarterly revenue was up 28.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.03) earnings per share. Equities analysts expect that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the sale, the director owned 15,344 shares of the company's stock, valued at $573,712.16. This represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.50% of the company's stock.

Institutional Trading of Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently bought and sold shares of the company. State of New Jersey Common Pension Fund D boosted its stake in Ultragenyx Pharmaceutical by 14.7% in the second quarter. State of New Jersey Common Pension Fund D now owns 53,040 shares of the biopharmaceutical company's stock worth $1,929,000 after buying an additional 6,804 shares in the last quarter. Ethic Inc. purchased a new stake in Ultragenyx Pharmaceutical in the second quarter worth approximately $241,000. Privium Fund Management B.V. boosted its stake in Ultragenyx Pharmaceutical by 1.4% in the second quarter. Privium Fund Management B.V. now owns 253,304 shares of the biopharmaceutical company's stock worth $9,185,000 after buying an additional 3,500 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Ultragenyx Pharmaceutical in the second quarter worth approximately $715,000. Finally, Nordea Investment Management AB boosted its stake in Ultragenyx Pharmaceutical by 59.8% in the second quarter. Nordea Investment Management AB now owns 60,176 shares of the biopharmaceutical company's stock worth $2,208,000 after buying an additional 22,509 shares in the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.